Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity

Uma Thanarajasingam, Noha Abdel-Wahab

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Mechanisms of immune checkpoints and their role in autoimmunity are discussed in the context of immune checkpoint inhibitor (ICI) therapy for cancer. The updated clinical spectrum of immune-related adverse events (irAEs), with an in-depth discussion of rheumatic irAEs, is presented. The relationship between ICI-induced loss of self-tolerance in cancer and the implications for understanding of irAEs, rheumatic irAEs in particular, is overviewed.

Original languageEnglish (US)
Pages (from-to)587-603
Number of pages17
JournalRheumatic Disease Clinics of North America
Volume46
Issue number3
DOIs
StatePublished - Aug 2020

Keywords

  • Autoimmunity
  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Rheumatic diseases
  • Tolerance

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity'. Together they form a unique fingerprint.

Cite this